Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN01195 in Advanced Solid Tumours
NCT06833008Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of IPN01195 in solid tumor (advanced stage), sponsored by Ipsen. Started Mar 2025; status: active, not recruiting.
02
Drugs
IPN01195
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06833008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833008.